Search
forLearn
5 / 801 resultslearn Defenscalp™
learn Latanoprost
glaucoma medication with hair follicle stimulant effects
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn acetyl tetrapeptide-3
Research
5 / 363 resultsresearch Pentacyclic TriterpenoidMaslinic Acid Promotes HairGrowth Comparable to Minoxidil: A New Insight on the Potential Involvementof Cilia Activity
Maslinic acid from olive extracts promotes hair growth like minoxidil.
research Pentacyclic Triterpenoid Maslinic Acid Promotes Hair Growth Comparable to Minoxidil: A New Insight on the Potential Involvement of Cilia Activity
Maslinic acid from olive extracts promotes hair growth like minoxidil.
research Ursolic acid, a pentacyclic triterpene from Ochrosia elliptica Labill leaves and its role in the management of polycystic ovary syndrome (PCOS)
Ursolic acid from Ochrosia elliptica leaves may help manage PCOS symptoms.
research The Acute Toxicity of 2,3,4,7,8-Pentachlorodibenzofuran (4PeCDF) in the Male Fischer Rat
4PeCDF is highly toxic to male rats, causing weight loss, organ damage, and death.
research Sericin hydrogels promote skin wound healing with effective regeneration of hair follicles and sebaceous glands after complete loss of epidermis and dermis
Sericin hydrogels heal skin wounds well, regrowing hair and glands with less scarring.
Community Join
5 / 1000+ resultscommunity Pelage Recruiting Now for Phase 2
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community Pelage, PP405, is creating a database for potential new trial volunteers
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.